Literature DB >> 2926165

Oral ribavirin therapy for subacute sclerosing panencephalitis.

J W Ogle1, P Toltzis, W D Parker, N Alvarez, K McIntosh, M J Levin, B A Lauer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2926165     DOI： 10.1093/infdis/159.4.748

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  12 in total

1.  High-dose intravenous ribavirin therapy for subacute sclerosing panencephalitis.

Authors:  M Hosoya; S Shigeta; S Mori; A Tomoda; S Shiraishi; T Miike; H Suzuki
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

Review 2.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

3.  Effective ribavirin concentration in hamster brains for antiviral chemotherapy for subacute sclerosing panencephalitis.

Authors:  T Ishii; M Hosoya; S Mori; S Shigeta; H Suzuki
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

4.  Mechanism of La Crosse virus inhibition by ribavirin.

Authors:  L F Cassidy; J L Patterson
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

5.  Effect of ribavirin on subacute sclerosing panencephalitis virus infections in hamsters.

Authors:  Y Honda; M Hosoya; T Ishii; S Shigeta; H Suzuki
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

6.  Aerosol and intraperitoneal administration of ribavirin and ribavirin triacetate: pharmacokinetics and protection of mice against intracerebral infection with influenza A/WSN virus.

Authors:  B E Gilbert; P R Wyde; S Z Wilson; R K Robins
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

7.  Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection.

Authors:  E Connor; S Morrison; J Lane; J Oleske; R L Sonke; J Connor
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

8.  A multi-step process of viral adaptation to a mutagenic nucleoside analogue by modulation of transition types leads to extinction-escape.

Authors:  Rubén Agudo; Cristina Ferrer-Orta; Armando Arias; Ignacio de la Higuera; Celia Perales; Rosa Pérez-Luque; Nuria Verdaguer; Esteban Domingo
Journal:  PLoS Pathog       Date:  2010-08-26       Impact factor: 6.823

9.  Potential benefits of sequential inhibitor-mutagen treatments of RNA virus infections.

Authors:  Celia Perales; Rubén Agudo; Hector Tejero; Susanna C Manrubia; Esteban Domingo
Journal:  PLoS Pathog       Date:  2009-11-13       Impact factor: 6.823

10.  Counteracting quasispecies adaptability: extinction of a ribavirin-resistant virus mutant by an alternative mutagenic treatment.

Authors:  Celia Perales; Rubén Agudo; Esteban Domingo
Journal:  PLoS One       Date:  2009-05-14       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.